Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

                    The meeting will be closed to the public in accordance with the                           ( print page 14573)                        provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.                

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Medication Discovery Using Rat Models of Relapse.                    

*Date:*                         April 14, 2009.                    

*Time:*                         9 a.m. to 3 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         Courtyard by Marriott Rockville, 2500 Research Boulevard, Rockville, MD 20850.                    

*Contact Person:*                         Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401, (301) 435-1439.                    

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Use of I/M Cross-Section and m/z as a Unique Identifier of Lipids and Neuropeptides in Complex Biosamples.                    

*Date:*                         April 15, 2009.                    

*Time:*                         9 a.m. to 12 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401, (301) 435-1439,                         *lf33c.nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; National Hispanic Science Network.                    

*Date:*                         April 16, 2009.                    

*Time:*                         11 a.m. to 1 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Minna Liang, PhD, Scientific Review Officer, Training and Special Projects Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, 6101 Executive Blvd., Room 220, MSC 8401, Bethesda, MD 20852, 301-435-1432,                         *liangm@nida.nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Educational Marketing.                    

*Date:*                         April 28, 2009.                    

*Time:*                         9:30 a.m. to 12 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401, (301) 435-1439,                         *lf33c.nih.gov*.                    

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Long Acting Bup for Opiate Maintenance.                    

*Date:*                         April 29, 2009.                    

*Time:*                         1 p.m. to 3 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Scott Chen, PhD, Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, Bethesda, MD 20892, 301-443-9511,                         *chensc@mail.nih.gov*.                    

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Novel Azetidine CB1 Antagonists.                    

*Date:*                         May 6, 2009.                    

*Time:*                         9:30 a.m. to 12:30 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401, (301)  435-1439,                         *lf33c.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: March 20, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-6787 Filed 3-30-09; 8:45 am]

BILLING CODE 4140-01-M